CD274 and cancer: One therapeutic approach against this is immune checkpoint inhibition therapy which uses anti-PD-L1 antibodies to inhibit the receptor-ligand interaction and subsequently promote anti-cancer T-cell-mediated immune response [5,6,7,8,9].